Immunicon Corporation Announces Independent Studies to Be Presented at 2007 San Antonio Breast Cancer Symposium That Confirm Utility of the CellSearch™ Circulating Tumor Cell Kit

admin Portfolio News

HUNTINGDON VALLEY, Pa. & SAN ANTONIO–(BUSINESS WIRE)–Immunicon Corporation (NASDAQ-CM:IMMC) announced today that three independent studies featuring Immunicon’s CellTracks® technology and the CellSearch™ Circulating Tumor Cell Kit will be presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS). The meeting is the premier educational and scientific event in breast oncology and will take place December 13-16 at the Henry B. Gonzalez Convention Center, San Antonio, Texas. Research conducted at MD Anderson, the University of Michigan, and the Lombardi Cancer Center at Georgetown University and others will be discussed at a Thursday December 13th afternoon session dedicated solely to circulating tumor cell research in breast cancer.

Dr. Massimo Cristofanilli, Co-Director of the first Inflammatory Breast Cancer Clinic at MD Anderson, is senior author on the abstract describing a large retrospective study involving 312 breast cancer patients evaluated between 2001 and 2007. The study confirms that CTCs are a strong independent predictor of survival in metastatic breast cancer and provides evidence supporting the use of CTCs as a new stratification method in patients with newly diagnosed Stage IV disease. The CellSearch™ test is currently FDA-cleared for monitoring patients with metastatic breast cancer or metastatic colorectal cancer.

Dr. Minetta Liu will present data indicating that the odds of disease progression are nearly five times higher for MBC patients with elevated CTC levels, based on a preliminary analysis of a study from the Lombardi Cancer Center at Georgetown University Medical Center. The authors propose that CTC measurement may therefore be particularly helpful in determining whether treatment is working in MBC patients in whom the disease cannot be accurately measured by conventional radiological methods. This group of patients represents approximately 40% of those currently being treated for MBC.

Results from a University of Michigan study will be presented showing for the first time that CellTracks® technology can be used to serially measure CTC in animals, indicating that the assay may be used in both the animal pre-clinical and human clinical phases of drug development.

Following the conference, the Immunicon presentations will be posted on Immunicon’s Web site at The CellSearch™ System includes instruments and assays that identify, enumerate and characterize CTCs from a blood test, was developed by Immunicon and is marketed by Veridex, LLC, a Johnson & Johnson Company, and will be on display at the Veridex booth # 7155 during the meeting. For more about the 2007 San Antonio Breast Cancer Symposium Annual Meeting, visit